Oral administration of Clostridium butyricum CGMCC0313-1 inhibitsβ-lactoglobulin-induced intestinal anaphylaxis in a mouse model of food allergy. Zhang J,Hui S,Li Q,Wu H,Liu M,Huang J,et al. Gut Pathog . 2017Zhang J, Hui S, Li Q, Wu H, Liu M, Huang J, et al. Oral administration...
Here we aimed to examine the effects of a naturally occurring butyrate-producing probioticclostridium butyricumCGMCC0313.1 (CB0313.1) in limiting the development of HFD-induced obesity. Mice treated with CB0313.1 exhibited reduced lipid accumulation in liver and serum, lower circulating insulin levels ...
Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic MiceLingling Jia, Dongyao Li, Ninghan Feng, Muhammad Shamoon, Zhenghua Sun, Lei Ding, Hao Zhang, Wei Chen, Jia Sun & Yong Q Chen ...
This study aimed at exploring whether Clostridium butyricum CGMCC0313 ‐1 ( C. butyricum ) can reduce ovalbumin ( OVA )‐induced allergic airway inflammation in a mouse model. Methods Mouse model of allergic airway inflammation induced via OVA was used in this study. C. butyricum was ...
AIM:To evaluate the therapeutic effects of a probiotic supplement(Clostridium butyricum,CGMCC0313)in a chemically-induced rat model of experimental colitis. METHODS:An experimental ulcerative colitis model was established by rectal injection of oxazolone into the colon of 40 Wistar rats randomly d...
Oral administration of Clostridium butyricum CGMCC0313-1 inhibits beta-lactoglobulin-induced intestinal anaphylaxis in a mouse model of food allergy. Gut Pathog. 2017, 9, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version] Gao, Q.X.; Qi, L.L.; Wu, T.X.; Xia, T.T.; Wang, J...